Company History

Mucosis was founded in 2007 and is built on the proprietary Mimopath® vaccine technology platform. The technology counts its origin at the Department of Molecular Genetics at the University of Groningen and Biomade Technology Foundation, the Netherlands. The company successfully secured funding (including non-dilutive) to advance its proof-of-concept program, FluGEM®, into a Phase I human clinical study in 2011 and to further develop its proprietary mucosal vaccine technology platform including its lead programs SynGEM and PneuGEM towards the clinic.

 

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >